Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresLong-Term Debt RepaymentsNet Cash FlowNet IncomeNon-cash ItemsOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Axsome Therapeutics (AXSM) Net Cash Flow (2022 - 2025)

Axsome Therapeutics (AXSM) has disclosed Net Cash Flow for 4 consecutive years, with -$2.3 million as the latest value for Q4 2025.

  • Quarterly Net Cash Flow rose 80.49% to -$2.3 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $7.6 million through Dec 2025, up 110.7% year-over-year, with the annual reading at $7.6 million for FY2025, 110.7% up from the prior year.
  • Net Cash Flow hit -$2.3 million in Q4 2025 for Axsome Therapeutics, down from $22.3 million in the prior quarter.
  • In the past five years, Net Cash Flow ranged from a high of $190.6 million in Q2 2023 to a low of -$54.8 million in Q1 2024.
  • Historically, Net Cash Flow has averaged $14.8 million across 4 years, with a median of -$6.8 million in 2022.
  • Biggest five-year swings in Net Cash Flow: skyrocketed 2687.71% in 2023 and later crashed 219.88% in 2024.
  • Year by year, Net Cash Flow stood at -$26.7 million in 2022, then decreased by 13.84% to -$30.4 million in 2023, then skyrocketed by 60.53% to -$12.0 million in 2024, then surged by 80.49% to -$2.3 million in 2025.
  • Business Quant data shows Net Cash Flow for AXSM at -$2.3 million in Q4 2025, $22.3 million in Q3 2025, and $2.1 million in Q2 2025.